An immunogenic personal neoantigen vaccine for patients with melanoma.
Level 4 - case-series / case-control
Phase I single-arm clinical trial (uncontrolled case series)
PubMed 28678778 · doi:10.1038/nature22991
What was done
In a Phase I clinical trial, six patients with melanoma received a personalized vaccine targeting up to 20 predicted personal tumor neoantigens identified through massively parallel sequencing and machine-learning HLA-binding prediction algorithms. The trial evaluated vaccine safety, feasibility, immune response (polyfunctional CD4+ and CD8+ T-cell activity against 97 total unique neoantigens), and clinical outcomes over a median follow-up of 25 months.
What was found
Vaccination generated CD4+ T-cell responses against 58 of 97 (60%) unique neoantigens and CD8+ T-cell responses against 15 of 97 (16%) unique neoantigens across the six patients. The induced T cells distinguished mutated from wild-type antigens and recognized autologous tumor. Clinically, 4 of the 6 patients remained recurrence-free at 25 months post-vaccination. The 2 patients who experienced disease recurrence received subsequent anti-PD-1 therapy and achieved complete tumor regression alongside expanded neoantigen-specific T-cell repertoires.
Why it matters
This study provides proof-of-concept in humans that multi-peptide personalized neoantigen vaccines are feasible to manufacture, safe, and capable of eliciting broad, mutation-specific T-cell responses that may synergize with immune checkpoint blockade.
Limits
The sample size was extremely small (n = 6 patients). The study lacked a control or comparator group, precluding causal determination of whether recurrence-free survival was driven by the vaccine, baseline prognosis, or prior surgical resection. Long-term efficacy and safety remain to be tested in larger, randomized controlled trials.